Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cue Biopharma Inc (CUE)
NASDAQ:CUE
Cue Biopharma (CUE) Stock Price & Analysis
488 Followers
CUE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.30 - $5.12
Previous Close$1.91
Volume30.59K
Average Volume (3M)295.46K
Market Cap
$95.34M
Enterprise Value$54.59M
Total Cash (Recent Filing)$54.69M
Total Debt (Recent Filing)$16.38M
Price to Earnings (P/E)-1.7
Beta2.07
Next Earnings
Sep 02, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.11
Shares Outstanding48,643,316
10 Day Avg. Volume418,265
30 Day Avg. Volume295,461
Standard Deviation0.21
R-Squared0.25
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)2.49
Price to Sales (P/S)74.61
Price to Cash Flow (P/CF)-3.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue14.29
Enterprise Value/Gross Profit43.84
Enterprise Value/Ebitda-1.07
Forecast
1Y Price Target
$9.40Price Target Upside379.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Cue Biopharma News
Bulls Say, Bears Say
Bulls Say
Financial StabilityThe company maintains a strong cash position, providing financial stability for ongoing research and development.
Product PipelineCUE-101 is moving towards a registrational path in combination with pembro, showing promising trial results.
Strategic PartnershipsCue Biopharma has a strategic partnership with Ono Pharmaceuticals, enhancing its business development potential.
Bears Say
EarningsThe company's collaboration revenue for 4Q23 was lower than analyst estimates.
Operational CostsResearch and Development as well as Sales, General and Administrative expenses were higher than expected for 4Q23.
Revenue PerformanceCue Biopharma's collaboration revenue for the quarter was lower than analyst estimates.
---
Ownership Overview
6.03% Insiders
7.29% Mutual Funds
8.66% Other Institutional Investors
78.03% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CUE FAQ
What was Cue Biopharma Inc’s price range in the past 12 months?
Cue Biopharma Inc lowest stock price was $1.30 and its highest was $5.12 in the past 12 months.
What is Cue Biopharma Inc’s market cap?
Currently, no data Available
When is Cue Biopharma Inc’s upcoming earnings report date?
Cue Biopharma Inc’s upcoming earnings report date is Sep 02, 2024 which is in 116 days.
How were Cue Biopharma Inc’s earnings last quarter?
Currently, no data Available
Is Cue Biopharma Inc overvalued?
According to Wall Street analysts Cue Biopharma Inc’s price is currently Undervalued.
Does Cue Biopharma Inc pay dividends?
Cue Biopharma Inc does not currently pay dividends.
What is Cue Biopharma Inc’s EPS estimate?
Cue Biopharma Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cue Biopharma Inc have?
Cue Biopharma Inc has 48,643,314 shares outstanding.
What happened to Cue Biopharma Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Cue Biopharma Inc?
Among the largest hedge funds holding Cue Biopharma Inc’s share is Slate Path Capital LP. It holds Cue Biopharma Inc’s shares valued at 6M.
---
Cue Biopharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.40 (379.59% Upside)
$9.40 (379.59% Upside)
Blogger Sentiment
Bullish
CUE Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 15.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 2.9%
Last 30 Days ▲ 2.9%
Last 30 Days ▲ 2.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-61.09%
12-Months-Change
Fundamentals
Return on Equity
-98.73%
Trailing 12-Months
Asset Growth
-32.59%
Trailing 12-Months
Company Description
Cue Biopharma Inc
Cue Biopharma, Inc. is a biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its pipeline includes Immuno-oncology, CUE-100 framework, CUE-200 framework, and autoimmune disease. The company was founded on December 31, 2014 and is headquartered in Cambridge, MA.
---
CUE Earnings Call
Q4 2024
0:00 / 0:00
---
CUE Stock 12 Month Forecast
Average Price Target
$9.40
▲(379.59% Upside)
Technical Analysis
Best Analysts Covering CUE
1 Year
1 Year Success Rate
3/11 ratings generated profit
1 Year Average Return
-31.75%
reiterated a buy rating last month
Copying Stephen Willey's trades and holding each position for 1 Year would result in 27.27% of your transactions generating a profit, with an average return of -31.75% per trade.
---